You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 3, 2024

Trilaciclib dihydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for trilaciclib dihydrochloride and what is the scope of freedom to operate?

Trilaciclib dihydrochloride is the generic ingredient in one branded drug marketed by Pharmacosmos and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Trilaciclib dihydrochloride has one hundred and thirty-five patent family members in twenty-seven countries.

One supplier is listed for this compound.

Summary for trilaciclib dihydrochloride
International Patents:135
US Patents:12
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 20
DailyMed Link:trilaciclib dihydrochloride at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for trilaciclib dihydrochloride
Generic Entry Date for trilaciclib dihydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for trilaciclib dihydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolPhase 2
Wake Forest University Health SciencesPhase 2
Merck Sharp & Dohme LLCPhase 2

See all trilaciclib dihydrochloride clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for trilaciclib dihydrochloride

US Patents and Regulatory Information for trilaciclib dihydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacosmos COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pharmacosmos COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Pharmacosmos COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pharmacosmos COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pharmacosmos COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Pharmacosmos COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Pharmacosmos COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for trilaciclib dihydrochloride

Country Patent Number Title Estimated Expiration
China 117530948 化疗方案期间免疫反应的保持 ⤷  Sign Up
China 110035759 化疗方案期间免疫反应的保持 (PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS) ⤷  Sign Up
Canada 3045465 PRESERVATION DE LA REPONSE IMMUNITAIRE LORS DE REGIMES CHIMIOTHERAPEUTIQUES (PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS) ⤷  Sign Up
Japan 6435315 ⤷  Sign Up
Japan 2023052449 化学療法の間の正常細胞の一時的な保護 ⤷  Sign Up
Portugal 2632467 ⤷  Sign Up
Spain 2761406 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.